1. Executive Summary
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Hospital Infection Therapeutics Market
4. Market Overview
    4.1. Market Segmentation
        4.1.1. Segment Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Hospital Infection Therapeutics Market Analysis and Forecast, 2023-2031
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
    5.3. COVID-19 Pandemic Impact on Industry
6. Hospital Infection Therapeutics Market Analysis and Forecast, by Therapeutics
    6.1. Introduction and Definitions
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Therapeutics, 2017–2031
        6.3.1. Anti-bacterial Drugs
        6.3.2. Anti-fungal Drugs
        6.3.3. Anti-viral Drugs
        6.3.4. Others
    6.4. Market Attractiveness, by Therapeutics
7. Global Hospital Infection Therapeutics Market Analysis and Forecast, by Infection
    7.1. Introduction and Definitions
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Infection, 2017–2031
        7.3.1. Hospital Acquired Pneumonia
        7.3.2. Urinary Tract Infections
        7.3.3. Gastrointestinal Disorders
        7.3.4. Bloodstream Infections
        7.3.5. Surgical Site Infections
        7.3.6. Other Hospital Infections
    7.4. Market Attractiveness, by Infection
8. Global Hospital Infection Therapeutics Market Analysis and Forecast, by Region
    8.1. Key Findings
    8.2. Market Value Forecast, by Region, 2017–2031
        8.2.1. North America
        8.2.2. Europe
        8.2.3. Asia Pacific
        8.2.4. Latin America
        8.2.5. Middle East & Africa
    8.3. Market Attractiveness, by Region
9. North America Hospital Infection Therapeutics Market Analysis and Forecast
    9.1. Introduction
        9.1.1. Key Findings
    9.2. Market Value Forecast, by Therapeutics, 2023–2031
        9.2.1. Anti-bacterial Drugs
        9.2.2. Anti-fungal Drugs
        9.2.3. Anti-viral Drugs
        9.2.4. Others
    9.3. Market Value Forecast, by Infection, 2023–2031
        9.3.1. Hospital Acquired Pneumonia
        9.3.2. Urinary Tract Infections
        9.3.3. Gastrointestinal Disorders
        9.3.4. Bloodstream Infections
        9.3.5. Surgical Site Infections
        9.3.6. Other Hospital Infections
    9.4. Market Value Forecast, by Country, 2023–2031
        9.4.1. U.S.
        9.4.2. Canada
    9.5. Market Attractiveness Analysis
        9.5.1. By Therapeutics
        9.5.2. By Infection
        9.5.3. By Country
10. Europe Hospital Infection Therapeutics Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Therapeutics, 2023–2031
        10.2.1. Anti-bacterial Drugs
        10.2.2. Anti-fungal Drugs
        10.2.3. Anti-viral Drugs
        10.2.4. Others
    10.3. Market Value Forecast, by Infection, 2023–2031
        10.3.1. Hospital Acquired Pneumonia
        10.3.2. Urinary Tract Infections
        10.3.3. Gastrointestinal Disorders
        10.3.4. Bloodstream Infections
        10.3.5. Surgical Site Infections
        10.3.6. Other Hospital Infections
    10.4. Market Value Forecast, by Country/Sub-region, 2023–2031
        10.4.1. Germany
        10.4.2. U.K.
        10.4.3. France
        10.4.4. Italy
        10.4.5. Spain
        10.4.6. Rest of Europe
    10.5. Market Attractiveness Analysis
        10.5.1. By Therapeutics
        10.5.2. By Infection
        10.5.3. By Country/Sub-region
11. Asia Pacific Hospital Infection Therapeutics Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Therapeutics, 2023–2031
        11.2.1. Anti-bacterial Drugs
        11.2.2. Anti-fungal Drugs
        11.2.3. Anti-viral Drugs
        11.2.4. Others
    11.3. Market Value Forecast, by Infection, 2023–2031
        11.3.1. Hospital Acquired Pneumonia
        11.3.2. Urinary Tract Infections
        11.3.3. Gastrointestinal Disorders
        11.3.4. Bloodstream Infections
        11.3.5. Surgical Site Infections
        11.3.6. Other Hospital Infections
    11.4. Market Value Forecast, by Country/Sub-region, 2023–2031
        11.4.1. China
        11.4.2. Japan
        11.4.3. India
        11.4.4. Australia & New Zealand
        11.4.5. Rest of Asia Pacific
    11.5. Market Attractiveness Analysis
        11.5.1. By Therapeutics
        11.5.2. By Infection
        11.5.3. By Country/Sub-region
12. Latin America Hospital Infection Therapeutics Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Therapeutics, 2023–2031
        12.2.1. Anti-bacterial Drugs
        12.2.2. Anti-fungal Drugs
        12.2.3. Anti-viral Drugs
        12.2.4. Others
    12.3. Market Value Forecast, by Infection, 2023–2031
        12.3.1. Hospital Acquired Pneumonia
        12.3.2. Urinary Tract Infections
        12.3.3. Gastrointestinal Disorders
        12.3.4. Bloodstream Infections
        12.3.5. Surgical Site Infections
        12.3.6. Other Hospital Infections
    12.4. Market Value Forecast, by Country/Sub-region, 2023–2031
        12.4.1. Brazil
        12.4.2. Mexico
        12.4.3. Rest of Latin America
    12.5. Market Attractiveness Analysis
        12.5.1. By Therapeutics
        12.5.2. By Infection
        12.5.3. By Country/Sub-region
13. Middle East & Africa Hospital Infection Therapeutics Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Therapeutics, 2023–2031
        13.2.1. Anti-bacterial Drugs
        13.2.2. Anti-fungal Drugs
        13.2.3. Anti-viral Drugs
        13.2.4. Others
    13.3. Market Value Forecast, by Infection, 2023–2031
        13.3.1. Hospital Acquired Pneumonia
        13.3.2. Urinary Tract Infections
        13.3.3. Gastrointestinal Disorders
        13.3.4. Bloodstream Infections
        13.3.5. Surgical Site Infections
        13.3.6. Other Hospital Infections
    13.4. Market Value Forecast, by Country/Sub-region, 2023–2031
        13.4.1. GCC Countries
        13.4.2. South Africa
        13.4.3. Rest of Middle East & Africa
    13.5. Market Attractiveness Analysis
        13.5.1. By Therapeutics
        13.5.2. By Infection
        13.5.3. By Country/Sub-region
14. Competition Landscape
    14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
    14.2. Market Share Analysis, by Company (2022)
    14.3. Company Profiles
        14.3.1. Merck & Co., Inc.
            14.3.1.1. Company Revenue
            14.3.1.2. Business Overview
            14.3.1.3. Product Segments
            14.3.1.4. Geographic Footprint
            14.3.1.5. Production Capacity/Plant Details, etc. (*As Applicable)
            14.3.1.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
        14.3.2. Pfizer, Inc.
            14.3.2.1. Company Revenue
            14.3.2.2. Business Overview
            14.3.2.3. Product Segments
            14.3.2.4. Geographic Footprint
            14.3.2.5. Production Capacity/Plant Details, etc. (*As Applicable)
            14.3.2.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
        14.3.3. GlaxoSmithKline plc
            14.3.3.1. Company Revenue
            14.3.3.2. Business Overview
            14.3.3.3. Product Segments
            14.3.3.4. Geographic Footprint
            14.3.3.5. Production Capacity/Plant Details, etc. (*As Applicable)
            14.3.3.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
        14.3.4. AstraZeneca
            14.3.4.1. Company Revenue
            14.3.4.2. Business Overview
            14.3.4.3. Product Segments
            14.3.4.4. Geographic Footprint
            14.3.4.5. Production Capacity/Plant Details, etc. (*As Applicable)
            14.3.4.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
        14.3.5. Johnson & Johnson Services, Inc.
            14.3.5.1. Company Revenue
            14.3.5.2. Business Overview
            14.3.5.3. Product Segments
            14.3.5.4. Geographic Footprint
            14.3.5.5. Production Capacity/Plant Details, etc. (*As Applicable)
            14.3.5.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
        14.3.6. F. Hoffmann-La Roche Ltd.
            14.3.6.1. Company Revenue
            14.3.6.2. Business Overview
            14.3.6.3. Product Segments
            14.3.6.4. Geographic Footprint
            14.3.6.5. Production Capacity/Plant Details, etc. (*As Applicable)
            14.3.6.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
        14.3.7. Bayer AG
            14.3.7.1. Company Revenue
            14.3.7.2. Business Overview
            14.3.7.3. Product Segments
            14.3.7.4. Geographic Footprint
            14.3.7.5. Production Capacity/Plant Details, etc. (*As Applicable)
            14.3.7.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
        14.3.8. Allergan plc.
            14.3.8.1. Company Revenue
            14.3.8.2. Business Overview
            14.3.8.3. Product Segments
            14.3.8.4. Geographic Footprint
            14.3.8.5. Production Capacity/Plant Details, etc. (*As Applicable)
            14.3.8.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
        14.3.9. Sanofi S.A.
            14.3.9.1. Company Revenue
            14.3.9.2. Business Overview
            14.3.9.3. Product Segments
            14.3.9.4. Geographic Footprint
            14.3.9.5. Production Capacity/Plant Details, etc. (*As Applicable)
            14.3.9.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
        14.3.10. Gilead Sciences, Inc.
            14.3.10.1. Company Revenue
            14.3.10.2. Business Overview
            14.3.10.3. Product Segments
            14.3.10.4. Geographic Footprint
            14.3.10.5. Production Capacity/Plant Details, etc. (*As Applicable)
            14.3.10.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
        14.3.11. Basilea Pharmaceutica Ltd.
            14.3.11.1. Company Revenue
            14.3.11.2. Business Overview
            14.3.11.3. Product Segments
            14.3.11.4. Geographic Footprint
            14.3.11.5. Production Capacity/Plant Details, etc. (*As Applicable)
            14.3.11.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
        14.3.12. Bristol-Myers Squibb Company
            14.3.12.1. Company Revenue
            14.3.12.2. Business Overview
            14.3.12.3. Product Segments
            14.3.12.4. Geographic Footprint
            14.3.12.5. Production Capacity/Plant Details, etc. (*As Applicable)
            14.3.12.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.